Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
23.76
-0.41 (-1.70%)
May 13, 2025, 4:00 PM - Market closed
Schrödinger Revenue
Schrödinger had revenue of $59.55M in the quarter ending March 31, 2025, with 62.72% growth. This brings the company's revenue in the last twelve months to $230.49M, up 22.29% year-over-year. In the year 2024, Schrödinger had annual revenue of $207.54M, down -4.21%.
Revenue (ttm)
$230.49M
Revenue Growth
+22.29%
P/S Ratio
7.51
Revenue / Employee
$258,689
Employees
891
Market Cap
1.74B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SDGR News
- 6 days ago - Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Schrödinger Reports Strong First Quarter 2025 Financial Results - Business Wire
- 8 days ago - Schrödinger to Present at BofA Securities 2025 Healthcare Conference - Business Wire
- 15 days ago - Schrödinger Presents New Preclinical Data at AACR Annual Meeting - Business Wire
- 20 days ago - Schrödinger to Announce First Quarter 2025 Financial Results on May 7 - Business Wire
- 25 days ago - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - Business Wire
- 4 weeks ago - Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) - Seeking Alpha